Nectar Lifesciences Limited (NECLIFE.BO)

INR 44.02

(0.0%)

Market Cap (In INR)

9.87 Billion

Revenue (In INR)

16.84 Billion

Net Income (In INR)

49.95 Million

Avg. Volume

541.71 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
26.2-56.39
PE
-
EPS
-
Beta Value
1.027
ISIN
INE023H01027
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Amit Chadah
Employee Count
-
Website
https://www.neclife.com
Ipo Date
2005-07-19
Details
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and mint derivatives and empty hard gelatin capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.